Anavex slips after CEO transition

[Ceo sign on wooden cubes. Ceo Concept.close up of wooden cubes,Business Concept.3D rendering on yellow background.]
fengdr/iStock via Getty Images

Shares of Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) fell ~3% on Wednesday after the Alzheimer’s drug developer named its former R&D head, Terrie Kellmeyer, as its interim chief executive following the departure of President and former CEO Christopher Missling.

Kellmeyer, a veteran in the pharmaceutical industry and Anavex’s (ANVX) former senior vice president of clinical development and current senior advisor, will lead the company’s next chapter in growth, the New York-based biotech said in a statement.

According to the company, Missling left his position on April 30 following a request from the board seeking his resignation.

Concurrently, Anavex (AVXL [https://seekingalpha.com/symbol/AVXL]) announced it will file a Form 12b-25 to extend the filing date for the 10-Q related to the quarter ending March 31, 2026.

“With a strong cash balance and no long-term debt, we will continue to focus on our lead candidate, oral blarcamesine, in early Alzheimer’s disease and begin to build out the appropriate team while creating long-term shareholder value," Kellmeyer added. [https://seekingalpha.com/pr/20502618-anavex-life-sciences-board-of-directors-appoints-former-senior-vice-president-of-clinical]

MORE ON ANAVEX LIFE SCIENCES

* Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory [https://seekingalpha.com/article/4867993-anavex-stock-negative-eu-opinion-leaves-blarcamesine-regulatory-purgatory]
* Anavex Life Sciences Corp. (AVXL) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4867711-anavex-life-sciences-corp-avxl-q1-2026-earnings-call-transcript]
* Anavex drops after pulling EU marketing application for Alzheimer’s therapy [https://seekingalpha.com/news/4568423-anavex-pulls-alzheimers-marketing-applicatio]
* Anavex outlines regulatory milestones for blarcamesine in 2026 while advancing ACCESS-AD participation [https://seekingalpha.com/news/4549055-anavex-outlines-regulatory-milestones-for-blarcamesine-in-2026-while-advancing-access-ad]
* Seeking Alpha’s Quant Rating on Anavex Life Sciences [https://seekingalpha.com/symbol/AVXL/ratings/quant-ratings]